Edition:
United Kingdom

OPKO Health Inc (OPK.OQ)

OPK.OQ on NASDAQ Stock Exchange Global Select Market

5.61USD
17 Aug 2018
Change (% chg)

$0.12 (+2.19%)
Prev Close
$5.49
Open
$5.46
Day's High
$5.63
Day's Low
$5.44
Volume
848,281
Avg. Vol
1,452,671
52-wk High
$7.24
52-wk Low
$2.66

Latest Key Developments (Source: Significant Developments)

OPKO Health Q2 Loss Per Share $0.01
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - OPKO Health Inc ::OPKO HEALTH REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.01.Q2 REVENUE $263.7 MILLION VERSUS I/B/E/S VIEW $261.7 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.07 -- THOMSON REUTERS I/B/E/S.  Full Article

OPKO Health Inc Says Intends To Remain On Tel Aviv Stock Exchange
Friday, 27 Apr 2018 

April 27 (Reuters) - OPKO Health Inc ::OPKO HEALTH INC - INTENDS TO REMAIN ON TEL AVIV STOCK EXCHANGE AND WITHDRAW ITS REQUEST TO VOLUNTARILY DELIST ITS COMMON STOCK FROM TASE.OPKO HEALTH TO REMAIN ON TEL AVIV STOCK EXCHANGE.OPKO HEALTH - HAVE SPOKEN WITH CO'S ISRAEL-BASED INVESTORS; THEY EXPRESSED DESIRE CO CONTINUE PRESENCE ON TASE AND URGED CO TO RECONSIDER DECISION.  Full Article

Opko Health qtrly loss per share $0.08‍​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Opko Health Inc ::Opko Health reports 2017 third quarter highlights and financial results.Q3 revenue $263.5 million versus I/B/E/S view $319.4 million.Opko Health Inc qtrly loss per share $0.08‍​.  Full Article

OPKO Health submits premarket approval application with FDA for PSA test
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - OPKO Health Inc :OPKO Health submits premarket approval application with FDA for a point-of-care PSA test with the Claros 1 platform.OPKO Health Inc - ‍filing contains clinical data from company's 864-patient total psa clinical study​.OPKO Health Inc - ‍OPKO expects to initiate clinical validation studies and to file a 510(k) application for a Claros 1 testosterone test in 2018​.OPKO Health - working to add additional tests for vitamin D, infectious diseases, cardiology, women's health, companion diagnostics to Claros 1 menu​.  Full Article

Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Xenetic Biosciences :Xenetic Biosciences enters into sublicense agreement related to its Polyxen technology with Baxalta Inc., a wholly-owned subsidiary of Shire Plc.Xenetic Biosciences Inc - ‍Xenetic to receive one-time payment of $7.5 million and single digit royalty payments based upon net sales​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee in Japan
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Opko Health Inc :Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee® in Japan.Opko Health Inc - ‍Under terms of agreement, JT will make an upfront payment to Opko of $6 million.Opko Health says unit ‍eirgen Pharma entered into an exclusive agreement with Japan Tobacco for development and commercialization in Japan of Rayaldee​.Opko Health - As per agrement, co eligible to receive up to additional $31 million in development & regulatory milestones & $75 million in sales based milestones​.Opko Health Inc - JT will make​ another ‍$6 million payment to co upon initiation of Opko's planned phase 2 study of Rayaldee in U.S. dialysis patients.  Full Article

Xenetic Biosciences reports Q2 loss per share $0.34
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - Xenetic Biosciences Inc :Xenetic biosciences reports 2017 second quarter financial results and provides business update.Qtrly loss per share $0.34.  Full Article

Opko Health CEO Phillip Frost reports purchase of 9,200 shares of co's common stock
Monday, 22 May 2017 

May 22 (Reuters) - Opko Health Inc :CEO Phillip Frost reports purchase of 9,200 shares of co's common stock on May 19 - SEC filing.  Full Article

BRIEF-Opko Health Reports Q1 Loss Per Share Of $0.08

* Q1 REVENUE $254.9 MILLION VERSUS I/B/E/S VIEW $236.9 MILLION